Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

19.2% of patients on Islatravir-Lenacapavir experienced mild adverse events, like dry mouth and nausea. The data was presented at the ID Week 2024. At 48 weeks, the investigational combination ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

Gilead plans to supply lenacapavir to generic manufacturers, priced at no-profit to the company, until they fully support demand. The agreements also cover lenacapavir for HIV prevention that is ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

The results from the PURPOSE 2 study, which builds on the 100% efficacy shown in PURPOSE 1, demonstrate lenacapavir's ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...